New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year | After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate,

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year. In their paper published in The Lancet journal,

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a